NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

美國的膀胱過動症治療藥的市場 (抗膽鹼促效劑,β-3腎上腺素受體激動劑):產業分析與未來展望

United States Overactive Bladder Market (Anticholinergics & Beta 3 Adrenoreceptor Agonists): Industry Analysis & Outlook (2020-2030)

出版商 Koncept Analytics 商品編碼 757839
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
美國的膀胱過動症治療藥的市場 (抗膽鹼促效劑,β-3腎上腺素受體激動劑):產業分析與未來展望 United States Overactive Bladder Market (Anticholinergics & Beta 3 Adrenoreceptor Agonists): Industry Analysis & Outlook (2020-2030)
出版日期: 2018年12月17日內容資訊: 英文 69 Pages
簡介

本報告提供美國國內的膀胱過動症 (OAB) 治療藥的市場相關分析,疾病概要和流行病學的狀態,患者數趨勢預測,OAB治療藥的市場規模趨勢預測,各產品詳細趨勢,OAB和前列腺肥大症 (BPH)的併發症的市場趨勢 (患者數,治療藥的市場規模),主要的推動及阻礙市場要素,企業間市場競爭的狀態,主要企業的簡介等相關調查。

第1章 市場概要

  • 關於膀胱過動症 (OAB)
  • 症狀與診斷
  • 治療
  • 膀胱過動症與前列腺肥大症 (BPH)的併發症

第2章 美國市場分析

  • 膀胱過動症 (OAB) 治療藥的市場
    • 膀胱過動症治療藥:市場規模的預測值 (以金額為準)
    • 膀胱過動症治療藥:市場規模,各類藥物
    • 抗膽鹼促效劑:市場規模的預測值 (以金額為準)
    • β-3腎上腺素受體激動劑:市場規模的預測值 (以金額為準)
    • β-3腎上腺素受體激動劑:各藥物的市場普及率
    • Vibegron:市場收益額的預測
    • Vibegron:處方數量的預測
    • Mirabegron:處方數量的預測
    • 膀胱過動症的患者數的預測
    • 膀胱過動症的治療完畢患者數的預測
    • 膀胱過動症治療藥的處方數量的預測
  • OAB、BPH併發症的治療藥的市場
    • OAB、BPH併發症的患者數的預測
    • β-3腎上腺素受體激動劑:市場規模的預測值 (以金額為準)
    • β-3腎上腺素受體激動劑:各藥物的市場普及率
    • Vibegron:市場收益額的預測
    • Vibegron:處方數量的預測
    • Mirabegron:處方數量的預測

第3章 市場動態

  • 成長促進因素
  • 主要趨勢和動靜
  • 課題

第4章 競爭環境

  • 全球市場
    • 市場收益額比較:各企業
    • 市場收益額和股票市值比較:各企業

第5章 企業簡介

  • Astellas Pharma Inc.
    • 產業概要
    • 主要的財務指標
    • 事業策略
  • 久光製藥
  • Pfizer Inc.
  • Allergan Plc.
目錄

Overactive bladder (OAB) syndrome is a chronic medical condition which has a significant impact on the quality of life in a major amount of the population. Overactive bladder is the name given to a group of urinary symptoms that include a strong, uncontrollable urge to urinate at unexpected times, which may result in urine leakage (incontinence), and frequent urination during the day and night. OAB affects performance of daily activities and social functions such as work, traveling, physical exercise, sleep, and sexual function. OAB is a prevalent condition that affects the lives of millions of adults in the US and around the world. An estimated 30 million Americans suffer from overactive bladder, which is uncomfortable, disturbing, and potentially severe.

The treatment approaches for OAB includes behavioral therapy, such as bladder training and pelvic floor exercises. Second line treatment includes pharmacological intervention, historically with anticholinergic medications and more recently with the novel Beta 3 agonist mirabegron. For patients with persistent OAB symptoms, third-line treatment includes procedural therapy using BOTOX injected directly into the bladder to induce temporary muscle paralysis or neuromodulation to enhance neural signals and inhibit reflex detrusor contraction.

The US Overactive Bladder market is set to experience favorable growth driven by factors such rising ageing population, increasing health care expenditure, growing obese population, surging diabetic prevalence and increasing coffee intake. The major trends observed in this market include advancing innovative therapies, increasing awareness for OAB and development of gene therapy. However, the growth of the market is constrained by challenges such as entry of generic drugs in the market, stringent regulations and side effects of oral therapies of OAB.

The report "United States Overactive Bladder Market (Anticholinergics & Beta 3 Adrenoreceptor Agonists): Industry Analysis & Outlook (2020-2030)" analyses the development of the respective market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Astellas Pharma Inc., Hisamitsu Pharmaceutical Co., Inc., Pfizer Inc. and Allergan Plc. are being profiled along with their key financials and strategies for growth.

Table of Contents

1. Market Overview

  • 1.1 Overactive Bladder
  • 1.2 Symptoms & Diagnosis
  • 1.3 Treatment
  • 1.4 Overactive Bladder with BPH

2. US Market Analysis

  • 2.1 Overactive Bladder Market
    • 2.1.1 US Overactive Bladder Market Forecast by Value
    • 2.1.2 US Overactive Bladder Market by Drug Class
    • 2.1.3 US Anticholinergics Market Forecast by Value
    • 2.1.4 US Beta 3 Adrenoreceptor Agonists Market Forecast by Value
    • 2.1.5 US Beta 3 Adrenoreceptor Agonists Market Penetration by Drug
    • 2.1.6 US Vibegron Drug Revenue Forecast
    • 2.1.7 US Vibegron Prescriptions Volume Forecast
    • 2.1.8 US Mirabegron Prescriptions Volume Forecast
    • 2.1.9 US Overactive Bladder Patient Population Forecast
    • 2.1.10 US Overactive Bladder Treated Patient Population Forecast
    • 2.1.11 US Overactive Bladder Prescriptions Volume Forecast
  • 2.2 Overactive Bladder Market with BPH
    • 2.2.1 US Overactive Bladder with BPH Patient Population Forecast
    • 2.2.2 US Beta 3 Adrenoreceptor Agoinst Market by Penetration Rate
    • 2.2.3 US Beta 3 Adrenoreceptor Agoinst Market Penetration by Drug
    • 2.2.4 US Vibegron Drug Revenue Forecast
    • 2.2.5 US Vibegron Prescriptions Volume Forecast
    • 2.2.6 US Mirabegron Prescriptions Volume Forecast

3. Market Dynamics

  • 3.1 Growth Drivers
    • 3.1.1 Rising Ageing Population
    • 3.1.2 Increasing Health Care Expenditure
    • 3.1.3 Growing Obese Population
    • 3.1.4 Surging Diabetic Prevalence
    • 3.1.5 Increasing Coffee Intake
  • 3.2 Key Trends & Development
    • 3.2.1 Advancing Innovative Therapies
    • 3.2.2 Rising Awareness for OAB
    • 3.2.3 Development of Gene Therapy
  • 3.3 Challenges
    • 3.3.1 Entry of Generic Drugs
    • 3.3.2 Stringent Regulations
    • 3.3.3 Side Effects of Oral Therapies

4. Competition

  • 4.1 Global Market
    • 4.1.1 Revenue Comparison by Company
    • 4.1.2 Market Cap Comparison by Company

5. Company Profiles

  • 5.1 Astellas Pharma Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Financial Overview
    • 5.1.3 Business Strategies
  • 5.2 Hisamitsu Pharmaceutical Co., Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Financial Overview
    • 5.2.3 Business Strategies
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Financial Overview
    • 5.3.3 Business Strategies
  • 5.4 Allergan Plc.
    • 5.4.1 Business Overview
    • 5.4.2 Financial Overview
    • 5.4.3 Business Strategies

List of Charts

  • Normal Bladder versus Overactive Bladder
  • OAB Treatment Approaches
  • US Overactive Bladder Market Forecast by Value (2020-2030)
  • US Overactive Bladder Market by Drug Class (2020/2030)
  • US Anticholinergics Market Forecast by Value (2020-2030)
  • US Beta 3 Adrenoreceptor Agonists Market Forecast by Value (2020-2030)
  • US Beta 3 Adrenoreceptor Agonists Market Penetration by Drug (2020/2024/2030)
  • US Vibegron Drug Revenue Forecast (2020-2030)
  • US Vibegron Prescriptions Volume Forecast (2020-2030)
  • US Mirabegron Prescriptions Volume Forecast (2020-2030)
  • US Overactive Bladder Patient Population Forecast (2020-2030)
  • US Overactive Bladder Treated Patient Population Forecast (2020-2030)
  • US Overactive Bladder Prescriptions Volume Forecast (2020-2030)
  • US Overactive Bladder with BPH Patient Population Forecast (2020-2030)
  • US Beta 3 Adrenoreceptor Agoinst Market by Penetration Rate (2020-2030)
  • US Beta 3 Adrenoreceptor Agoinst Market Penetration by Drug (2021/2024/2030)
  • US Vibegron Drug Revenue Forecast (2021-2030)
  • US Vibegron Prescriptions Volume Forecast (2021-2030)
  • US Mirabegron Prescriptions Volume Forecast (2021-2030)
  • US Ageing Population (65 years & Above) (2013-2017)
  • US Healthcare Expenditure; 1990-2020 (%)
  • US Obese Population (20 years & Above) (2008-2017)
  • US Diagnosed Diabetic Population (2010-2017)
  • Domestic Consumption of Coffee in the US (2014-2018)
  • Revenue Comparison by Company (2017)
  • Market Cap Comparison by Company (2017)
  • Astellas Pharma Sales by Business Segments (2018)
  • Astellas Pharma Sales and Net Income (2014-2018)
  • Hisamitsu Pharmaceutical Sales by Business Segments (2018)
  • Hisamitsu Pharma Net Sales and Net Income (2014-2018)
  • Hisamitsu Pharmaceutical Research & Development Expenditure (2014-2018)
  • Pfizer Inc.'s Revenue Share by Major Business Segment (2017)
  • Pfizer Inc.'s Revenue and Net Income (2013-2017)
  • Pfizer Inc. R&D Expenses (2015-2017)
  • Allergan Plc Net Revenues by Business Segments (2017)
  • Allergan Plc Net Revenues and Net Income (Loss) (2013-2017)
  • Allergan Plc Research and Development Expenditures (2015-2017)

List of Tables

  • Astellas Pharma Major Product Approvals & Launches (2018)
  • Hisamitsu Pharmaceutical Product Approvals (2018)
  • Major Business Segments of the Pfizer Inc. (2017)
  • Pfizer Major Agreements (2018)